Literature DB >> 18331585

Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells.

Francisco Molina-Holgado1, Alessandra Gaeta, Paul T Francis, Robert J Williams, Robert C Hider.   

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disorder, but the initiating molecular processes contributing to neuronal death are not well understood. AD is associated with elevated soluble and aggregated forms of amyloid beta (Abeta) and with oxidative stress. Furthermore, there is increasing evidence for a detrimental role of iron in the pathogenic process. In this context, iron chelation by compounds such as 3-hydroxypyridin-4-one, deferiprone (Ferriprox) may have potential neuroprotective effects. We have evaluated the possible neuroprotective actions of deferiprone against a range of AD-relevant insults including ferric iron, H(2)O(2) and Abeta in primary mouse cortical neurones. We have investigated the possible neuroprotective actions of deferiprone (1, 3, 10, 30 or 100 microM) in primary neuronal cultures following exposure to ferric iron [ferric nitrilotriacetate (FeNTA); 3 and 10 microM], H(2)O(2) (100 microM) or Abeta1-40 (3, 10 and 20 microM). Cultures were treated with deferiprone or vehicle either immediately or up to 6 h after the insult in a 24-well plate format. In order to elucidate a possible neuroprotective action of deferiprone against Parkinson's disease relevant insults another group of experiments were performed in the human neuroblastoma catecholaminergic SHSY-5Y cell line. SHSY-5Y cells were treated with MPP(+) iodide, the active metabolite of the dopaminergic neurotoxin MPTP and the neuroprotective actions of deferiprone evaluated. Cytotoxicity was assessed at 24 h by lactate dehydrogenase release, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide turnover (FeNTA and hydrogen peroxide) and morphometric analysis of cell viability by Hoechst 33324/propidium iodide (FeNTA, Abeta and MPP(+)) or 6-carboxyfluorescein diacetate and annexin V-Cy3 (Abeta). The present study demonstrates that deferiprone protects against FeNTA, hydrogen peroxide, MPP(+) and Abeta1-40-induced neuronal cell death in vitro, which is consistent with previous in vitro and in vivo studies that have demonstrated similar protection with other iron chelators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18331585     DOI: 10.1111/j.1471-4159.2008.05332.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

1.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

Review 3.  Treating Alzheimer's disease by targeting iron.

Authors:  Sara Nikseresht; Ashley I Bush; Scott Ayton
Journal:  Br J Pharmacol       Date:  2019-02-11       Impact factor: 8.739

4.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

Review 5.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

6.  Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone.

Authors:  Pamela Maher; George J Kontoghiorghes
Journal:  Neurochem Res       Date:  2015-01-06       Impact factor: 3.996

Review 7.  Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Matthew K McElwee; Katharine Horback; Amber Beserra
Journal:  Antioxid Redox Signal       Date:  2014-02-27       Impact factor: 8.401

8.  A multidimensional approach to an in-depth proteomics analysis of transcriptional regulators in neuroblastoma cells.

Authors:  Qing Li; Mohit Raja Jain; Wei Chen; Hong Li
Journal:  J Neurosci Methods       Date:  2013-04-01       Impact factor: 2.390

9.  Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.

Authors:  Donna W Lee; Subramanian Rajagopalan; Ambreena Siddiq; Roberto Gwiazda; Lichuan Yang; M Flint Beal; Rajiv R Ratan; Julie K Andersen
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

Review 10.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.